BTK and neoplasm: Ibrutinib treatment, Btk deficiency or siRNA-mediated knockdown of BTK shifts macrophage polarization from tumor-promoting M2-like macrophages toward inflammatory M1-like and diminishes PD-1 and SIRPα expression on macrophages (24, 77, 86, 87).